Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01591629 · ClinicalTrials.gov registry record · Early Phase 1
The Effects of ∆-9-THC and Naloxone in Humans
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT01591629 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 6 participants.
The verdict
NCT01591629, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this project is to examine the effects of mu-opiate antagonism on the rewarding and reinforcing effects of delta-9-tetrahydrocannabinol (THC), the main psychoactive ingredient of cannabis.
Interventions
- DRUG Placebo
- DRUG Naloxone
- DRUG Delta-9-THC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-11-04 |
| Est. Completion | 2012-06-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01591629
The ClinicalTrials.gov registry entry for NCT01591629 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01591629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01591629 about?
NCT01591629 is a clinical study titled "The Effects of ∆-9-THC and Naloxone in Humans". The purpose of this project is to examine the effects of mu-opiate antagonism on the rewarding and reinforcing effects of delta-9-tetrahydrocannabinol (THC), the main psychoactive ingredient of cannabis.
What is the current status of trial NCT01591629?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2011-11-04. Estimated completion is 2012-06-01.
What interventions are being tested in trial NCT01591629?
The interventions under investigation include: Placebo (DRUG), Naloxone (DRUG), Delta-9-THC (DRUG).
Who is sponsoring clinical trial NCT01591629?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.